Literature DB >> 1708279

Lysis of interferon-gamma activated Schwann cell by cross-reactive CD8+ alpha/beta T cells with specificity for the mycobacterial 65 kd heat shock protein.

U Steinhoff1, B Schoel, S H Kaufmann.   

Abstract

Heat shock protein (hsp) 65 is a major T cell antigen of Mycobacterium leprae. The hsp 65 of M. leprae is nearly identical in M. bovis/M. tuberculosis (greater than 95% protein sequence homology) and surprisingly similar in man (65% protein sequence homology). Recently, we had provided evidence in a murine model that CD8+ T cells recognize and lyse Schwann cells presenting M. leprae antigen in the context of major histocompatibility (MHC) class I gene products. Because murine Schwann cells are class I negative, antigen presentation requires prior stimulation with interferon-gamma (IFN-gamma). CD8+ T cells were activated against tryptic fragments of mycobacterial hsp 65. These T cells recognized epitopes of hsp 65 which had been generated through the cytoplasmic class I processing pathway. They were also capable of lysing Schwann cells which had been activated by IFN-gamma and not primed with nominal hsp 65 peptides. In contrast, T cells activated against tryptic ova peptides only lysed Schwann cells which had been both stimulated with IFN-gamma and primed with ova peptides. Evidence is presented that class I (H-2D) restricted, CD8+ alpha/beta T lymphocytes with specificity for the mycobacterial hsp 65 recognize IFN-gamma-stimulated Schwann cells probably because they are specific for a(n) epitope(s) shared by the bacterial hsp and a host cognate. Activation of autoreactive T cells with specificity to shared epitopes could contribute to nerve damage in tuberculoid leprosy which is characterized by low to absent M. leprae in Schwann cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1708279     DOI: 10.1093/intimm/2.3.279

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  14 in total

Review 1.  The cellular immune response to heat shock proteins.

Authors:  S H Kaufmann
Journal:  Experientia       Date:  1992-07-15

Review 2.  Neuronal elements in the pathogenesis of type 1 diabetes.

Authors:  Hubert Tsui; Shawn Winer; George Jakowsky; H-Michael Dosch
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 3.  Heat-shock proteins and pathogenesis of bacterial infections.

Authors:  S H Kaufmann
Journal:  Springer Semin Immunopathol       Date:  1991

Review 4.  A reappraisal of the evidence that rheumatoid arthritis and several other idiopathic diseases are slow bacterial infections.

Authors:  G A Rook; P M Lydyard; J L Stanford
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

5.  Lack of cytotoxic activity against Mycobacterium leprae 65-kD heat shock protein (hsp) in multibacillary leprosy patients.

Authors:  S de la Barrera; S Fink; M Finiasz; F Minnucci; R Valdez; L M Baliña; M C Sasiain
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

6.  hsp70 synthesis in Schwann cells in response to heat shock and infection with Mycobacterium leprae.

Authors:  Y Mistry; D B Young; R Mukherjee
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

Review 7.  Role of heat shock proteins in protection from and pathogenesis of infectious diseases.

Authors:  U Zügel; S H Kaufmann
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

Review 8.  Rheumatoid arthritis: how well do the theories fit the evidence?

Authors:  J McCulloch; P M Lydyard; G A Rook
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

Review 9.  Heat-shock proteins and autoimmunity in humans.

Authors:  P Res; J Thole; R de Vries
Journal:  Springer Semin Immunopathol       Date:  1991

10.  Autoantibodies to cerebroside sulphate (sulphatide) in leprosy.

Authors:  P R Wheeler; J G Raynes; K P McAdam
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.